Auvi-q is a drug owned by Kaleo Inc. It is protected by 32 US drug patents filed from 2013 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 21, 2037. Details of Auvi-q's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10688244 | Medicament delivery device and methods for delivering drugs to infants and children |
Dec, 2037
(13 years from now) | Active |
| US11771830 | Medicament delivery device and methods for delivering drugs to infants and children |
Dec, 2037
(13 years from now) | Active |
| US10842938 | Medicament delivery device and methods for delivering drugs to infants and children |
Dec, 2037
(13 years from now) | Active |
| US8021344 | Medicament delivery device configured to produce an audible output |
Nov, 2029
(4 years from now) | Active |
| US8226610 | Medical injector with compliance tracking and monitoring |
Apr, 2029
(4 years from now) | Active |
| US8231573 | Medicament delivery device having an electronic circuit system |
Nov, 2028
(4 years from now) | Active |
| US7749194 | Devices, systems, and methods for medicament delivery |
Oct, 2028
(3 years from now) | Active |
| US7947017 | Devices, systems and methods for medicament delivery |
Mar, 2028
(3 years from now) | Active |
| US9724471 | Devices, systems, and methods for medicament delivery |
May, 2027
(2 years from now) | Active |
| US8206360 | Devices, systems and methods for medicament delivery |
Feb, 2027
(2 years from now) | Active |
| US9238108 | Medicament delivery device having an electronic circuit system |
Feb, 2027
(2 years from now) | Active |
| US11590286 | Devices, systems and methods for medicament delivery |
Dec, 2026
(2 years from now) | Active |
| US10960155 | Devices, systems and methods for medicament delivery |
Jun, 2026
(1 year, 7 months from now) | Active |
| US7731686 | Devices, systems and methods for medicament delivery |
Jun, 2026
(1 year, 6 months from now) | Active |
| US8926594 | Devices, systems and methods for medicament delivery |
Mar, 2026
(1 year, 4 months from now) | Active |
| US9259539 | Devices, systems and methods for medicament delivery |
Feb, 2026
(1 year, 2 months from now) | Active |
| US9278182 | Devices, systems and methods for medicament delivery |
Feb, 2026
(1 year, 2 months from now) | Active |
| US9149579 | Devices, systems and methods for medicament delivery |
Jul, 2025
(8 months from now) | Active |
| US10335549 | Devices, systems and methods for medicament delivery |
Apr, 2025
(5 months from now) | Active |
| US8016788 | Devices, systems and methods for medicament delivery |
Mar, 2025
(4 months from now) | Active |
| US7731690 | Devices, systems and methods for medicament delivery |
Jan, 2025
(a month from now) | Active |
| US10314977 | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 days from now) | Active |
| US8920377 | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 days from now) | Active |
| US9056170 | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 days from now) | Active |
| US7918823 | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 days from now) | Active |
| US9833573 | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 days from now) | Active |
| US8313466 | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 days from now) | Active |
| US10737028 | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 days from now) | Active |
| US9737669 | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 days from now) | Active |
| US8361029 | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 days from now) | Active |
| US8425462 | Devices, systems, and methods for medicament delivery |
Nov, 2024
(7 days from now) | Active |
| US8608698 | Devices, systems and methods for medicament delivery |
Nov, 2024
(7 days from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Auvi-q's patents.
Latest Legal Activities on Auvi-q's Patents
Given below is the list of recent legal activities going on the following patents of Auvi-q.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 May, 2024 | US10842938 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 May, 2024 | US8313466 |
| Maintenance Fee Reminder Mailed Critical | 01 Apr, 2024 | US10737028 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 31 Jan, 2024 | US8231573 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Jan, 2024 | US8226610 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Dec, 2023 | US10688244 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Dec, 2023 | US8206360 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Large Entity | 13 Dec, 2023 | US9259539 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Dec, 2023 | US9259539 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Large Entity | 13 Dec, 2023 | US9278182 |
US patents provide insights into the exclusivity only within the United States, but Auvi-q is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Auvi-q's family patents as well as insights into ongoing legal events on those patents.
Auvi-q's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Auvi-q's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 21, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Auvi-q Generic API suppliers:
Epinephrine is the generic name for the brand Auvi-q. 4 different companies have already filed for the generic of Auvi-q, with Am Regent having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Auvi-q's generic
Alternative Brands for Auvi-q
Auvi-q which is used for treating severe allergic reactions in patients with a weight between 7.5 to 15 kg., has several other brand drugs in the same treatment category and using the same active ingredient (Epinephrine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Kaleo Inc |
| |||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Epinephrine. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Adamis Pharms Corp |
| |||
| Armstrong Pharms |
| |||
| Ars Pharms Operation |
| |||
| Baxter Hlthcare Corp |
| |||
| Bpi Labs |
| |||
| Endo Operations |
| |||
| Impax |
| |||
| Inforlife |
| |||
| Long Grove Pharms |
| |||
| Mylan Speciality Lp |
| |||
| Vyteris |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Epinephrine, Auvi-q's active ingredient. Check the complete list of approved generic manufacturers for Auvi-q
About Auvi-q
Auvi-Q is a drug owned by Kaleo Inc. It is used for treating severe allergic reactions in patients with a weight between 7.5 to 15 kg. Auvi-Q uses Epinephrine as an active ingredient. Auvi-Q was launched by Kaleo Inc in 2017.
Approval Date:
Auvi-q was approved by FDA for market use on 17 November, 2017.
Active Ingredient:
Auvi-q uses Epinephrine as the active ingredient. Check out other Drugs and Companies using Epinephrine ingredient
Treatment:
Auvi-q is used for treating severe allergic reactions in patients with a weight between 7.5 to 15 kg.
Dosage:
Auvi-q is available in solution form for intramuscular, subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.1MG/DELIVERY | SOLUTION | Prescription | INTRAMUSCULAR, SUBCUTANEOUS |
| EQ 0.15MG/DELIVERY | SOLUTION | Prescription | INTRAMUSCULAR, SUBCUTANEOUS |
| EQ 0.3MG/DELIVERY | SOLUTION | Prescription | INTRAMUSCULAR, SUBCUTANEOUS |